vs
Side-by-side financial comparison of BrightSpire Capital, Inc. (BRSP) and Cytek Biosciences, Inc. (CTKB). Click either name above to swap in a different company.
BrightSpire Capital, Inc. is the larger business by last-quarter revenue ($83.2M vs $62.1M, roughly 1.3× Cytek Biosciences, Inc.). BrightSpire Capital, Inc. runs the higher net margin — -17.3% vs -70.9%, a 53.7% gap on every dollar of revenue. On growth, Cytek Biosciences, Inc. posted the faster year-over-year revenue change (8.1% vs -0.4%). BrightSpire Capital, Inc. produced more free cash flow last quarter ($55.1M vs $-1.8M). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs -6.8%).
Oakley Capital Investments, is a large British investment trust focused on investments in mid-market companies in the business services, consumer, education and technology sectors. The company is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
BRSP vs CTKB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $83.2M | $62.1M |
| Net Profit | $-14.4M | $-44.1M |
| Gross Margin | — | 52.9% |
| Operating Margin | — | -9.0% |
| Net Margin | -17.3% | -70.9% |
| Revenue YoY | -0.4% | 8.1% |
| Net Profit YoY | 27.3% | -557.1% |
| EPS (diluted) | $-0.11 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $83.2M | $62.1M | ||
| Q3 25 | $83.9M | $52.3M | ||
| Q2 25 | $85.9M | $45.6M | ||
| Q1 25 | $77.6M | $41.5M | ||
| Q4 24 | $83.5M | $57.5M | ||
| Q3 24 | $88.2M | $51.5M | ||
| Q2 24 | $91.4M | $46.6M | ||
| Q1 24 | $95.8M | $44.9M |
| Q4 25 | $-14.4M | $-44.1M | ||
| Q3 25 | $984.0K | $-5.5M | ||
| Q2 25 | $-23.1M | $-5.6M | ||
| Q1 25 | $5.3M | $-11.4M | ||
| Q4 24 | $-19.7M | $9.6M | ||
| Q3 24 | $12.7M | $941.0K | ||
| Q2 24 | $-67.9M | $-10.4M | ||
| Q1 24 | $-57.1M | $-6.2M |
| Q4 25 | — | 52.9% | ||
| Q3 25 | — | 52.7% | ||
| Q2 25 | — | 52.3% | ||
| Q1 25 | — | 48.6% | ||
| Q4 24 | — | 58.5% | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 54.6% | ||
| Q1 24 | — | 51.3% |
| Q4 25 | — | -9.0% | ||
| Q3 25 | -1.7% | -17.6% | ||
| Q2 25 | -54.5% | -23.3% | ||
| Q1 25 | 5.1% | -36.1% | ||
| Q4 24 | -24.9% | 5.2% | ||
| Q3 24 | 13.2% | -8.2% | ||
| Q2 24 | -74.9% | -18.3% | ||
| Q1 24 | -59.4% | -23.9% |
| Q4 25 | -17.3% | -70.9% | ||
| Q3 25 | 1.2% | -10.5% | ||
| Q2 25 | -26.9% | -12.2% | ||
| Q1 25 | 6.9% | -27.5% | ||
| Q4 24 | -23.7% | 16.8% | ||
| Q3 24 | 14.4% | 1.8% | ||
| Q2 24 | -74.2% | -22.4% | ||
| Q1 24 | -59.6% | -13.8% |
| Q4 25 | $-0.11 | — | ||
| Q3 25 | $0.00 | — | ||
| Q2 25 | $-0.19 | — | ||
| Q1 25 | $0.04 | — | ||
| Q4 24 | $-0.16 | — | ||
| Q3 24 | $0.09 | — | ||
| Q2 24 | $-0.53 | — | ||
| Q1 24 | $-0.45 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $66.8M | $90.9M |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $938.4M | $341.7M |
| Total Assets | $3.6B | $461.5M |
| Debt / EquityLower = less leverage | 2.63× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $66.8M | $90.9M | ||
| Q3 25 | $113.4M | $93.3M | ||
| Q2 25 | $154.3M | $75.5M | ||
| Q1 25 | $200.9M | $95.3M | ||
| Q4 24 | $302.2M | $98.7M | ||
| Q3 24 | $263.8M | $162.3M | ||
| Q2 24 | $203.3M | $177.9M | ||
| Q1 24 | $221.5M | $168.8M |
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.3B | — | ||
| Q1 25 | $2.3B | — | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $2.6B | — | ||
| Q2 24 | $2.5B | — | ||
| Q1 24 | $2.6B | — |
| Q4 25 | $938.4M | $341.7M | ||
| Q3 25 | $976.4M | $378.6M | ||
| Q2 25 | $994.4M | $377.6M | ||
| Q1 25 | $1.0B | $379.6M | ||
| Q4 24 | $1.0B | $395.7M | ||
| Q3 24 | $1.1B | $385.5M | ||
| Q2 24 | $1.1B | $389.1M | ||
| Q1 24 | $1.2B | $392.6M |
| Q4 25 | $3.6B | $461.5M | ||
| Q3 25 | $3.3B | $494.9M | ||
| Q2 25 | $3.4B | $493.3M | ||
| Q1 25 | $3.6B | $482.6M | ||
| Q4 24 | $3.7B | $499.5M | ||
| Q3 24 | $3.8B | $491.2M | ||
| Q2 24 | $3.8B | $483.7M | ||
| Q1 24 | $3.9B | $492.1M |
| Q4 25 | 2.63× | — | ||
| Q3 25 | 2.22× | — | ||
| Q2 25 | 2.27× | — | ||
| Q1 25 | 2.27× | — | ||
| Q4 24 | 2.38× | — | ||
| Q3 24 | 2.36× | — | ||
| Q2 24 | 2.28× | — | ||
| Q1 24 | 2.17× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $73.0M | $-771.0K |
| Free Cash FlowOCF − Capex | $55.1M | $-1.8M |
| FCF MarginFCF / Revenue | 66.2% | -2.9% |
| Capex IntensityCapex / Revenue | 21.6% | 1.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $102.0M | $-8.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $73.0M | $-771.0K | ||
| Q3 25 | $29.9M | $-3.9M | ||
| Q2 25 | $17.4M | $108.0K | ||
| Q1 25 | $10.5M | $-125.0K | ||
| Q4 24 | $103.4M | $2.0M | ||
| Q3 24 | $31.3M | $13.2M | ||
| Q2 24 | $22.9M | $6.2M | ||
| Q1 24 | $24.6M | $4.0M |
| Q4 25 | $55.1M | $-1.8M | ||
| Q3 25 | $27.4M | $-4.6M | ||
| Q2 25 | $11.6M | $-1.5M | ||
| Q1 25 | $8.0M | $-974.0K | ||
| Q4 24 | $97.3M | $1.1M | ||
| Q3 24 | $28.3M | $12.2M | ||
| Q2 24 | $22.7M | $5.2M | ||
| Q1 24 | $22.2M | $3.4M |
| Q4 25 | 66.2% | -2.9% | ||
| Q3 25 | 32.7% | -8.7% | ||
| Q2 25 | 13.4% | -3.2% | ||
| Q1 25 | 10.3% | -2.3% | ||
| Q4 24 | 116.6% | 1.9% | ||
| Q3 24 | 32.1% | 23.7% | ||
| Q2 24 | 24.9% | 11.0% | ||
| Q1 24 | 23.2% | 7.6% |
| Q4 25 | 21.6% | 1.6% | ||
| Q3 25 | 2.9% | 1.3% | ||
| Q2 25 | 6.8% | 3.5% | ||
| Q1 25 | 3.2% | 2.0% | ||
| Q4 24 | 7.3% | 1.6% | ||
| Q3 24 | 3.4% | 2.0% | ||
| Q2 24 | 0.1% | 2.3% | ||
| Q1 24 | 2.5% | 1.3% |
| Q4 25 | — | — | ||
| Q3 25 | 30.36× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.97× | — | ||
| Q4 24 | — | 0.21× | ||
| Q3 24 | 2.46× | 14.05× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BRSP
Segment breakdown not available.
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
